Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Sonic (ASX:SHL) share price on watch with Canberra deal

The Sonic Healthcare Ltd (ASX:SHL) share price is on watch after revealing a large acquisition called Canberra Imaging Group.

The Sonic Healthcare Ltd (ASX: SHL) share price is on watch after revealing a large acquisition called Canberra Imaging Group.

What is Canberra Imaging Group?

Sonic called the CIG acquisition a significant and positive step in developing its imaging division in Australia. The deal will broaden its footprint, deepen its talent pool, increase the revenue of the division by around 10% and offer the potential opportunity for synergy benefits.

CIG has annual revenue of around $60 million. It’s the leading radiology practice in Canberra, with branches in Goulburn and Queanbeyan in NSW.

The practice, with a history going back more than 50 years, employs 15 radiologists and has 10 service sites across nine locations.

CIG operates one fully-funded (through Medicare), two partially funded and tow unlicensed MRI scanners and also operates one of two PET CT scanners in Canberra. It is the only private operator of an angiography and interventional day suite in the area.

The acquisition is going to be funded from cash and/or available debt lines and will immediately add to profit / earnings per share (EPS). Settlement is expected in the first quarter of FY22.

Management comments

Sonic Healthcare CEO Dr Colin Goldschmidt said: “Canberra Imaging Group is a high-quality imaging practice, with outstanding radiologists, management and staff, and with a culture that is strongly aligned with Sonic’s medical leadership model. CIG has a proven track record in the greater Canberra market, with a history of strong organic growth based on personalised and excellent customer service. I am delighted to welcome warmly all CIG staff to the Sonic Healthcare group.”

Summary thoughts on Sonic and the share price

Sonic is one of the best healthcare businesses on the ASX in my opinion. It offers integral services for the healthcare sector with its pathology and imaging services. Sonic has been very important for testing for COVID-19 over the last 15 months.

This acquisition will help Sonic hang onto this elevated level of profit. However, I also believe that COVID-19 testing is going to last longer than expected. Based on CommSec projections, Sonic shares are valued at 22 times the estimated earnings for the 2022 financial year.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content